0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Antibodies > Rituximab > Anti-Rituximab Antibodies (recommended for PK/PD)

Anti-Rituximab Antibodies (recommended for PK/PD)

  • Source
    Mouse monoclonal antibody is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with Rituximab F(ab')2.
  • Isotype
    IgG1/kappa
  • Specificity
    Recognizes Rituximab specifically, no cross reactivity with other humanized antibodies.
  • Purity

    >95% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Gly, 25mM Arg, 150 mM NaCl, pH7.5.. Normally trehalose is added as protectant before lyophilization.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    No activity loss was observed after storage at:

    1. 4-8°C for 12 months in lyophilized state;

    2. -70°C for 3 years under sterile conditions after reconstitution.

SDS-PAGE
Anti-Rituximab Antibodies (recommended for PK/PD) (Cat. No. RIB-Y37) SDS-PAGE gel

Anti-Rituximab Antibodies (recommended for PK/PD) on SDS-PAGE  under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

Bioactivity-ELISA
Anti-Rituximab Antibodies (recommended for PK/PD)Anti-Rituximab Antibodies (recommended for PK/PD) (Cat. No. RIB-Y37) ELISA bioactivity

Detection of rituximab by bridging ELISA in serum. Immobilized Anti-Rituximab Antibodies (Cat. No. RIB-Y37) at 2 μg/ml, added increasing concentrations of rituximab (10% human serum) and then added Biotinylated Anti-Rituximab Antibodies (Cat. No. RIB-BY35) at 1 μg/ml. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 1 ng/ml.

Anti-Rituximab Antibodies (recommended for PK/PD)Anti-Rituximab Antibodies (recommended for PK/PD) (Cat. No. RIB-Y37) ELISA bioactivity

Demonstration of the specificity of Anti-Rituximab Antibodies (Cat. No. RIB-Y37) to the rituximab.

Bioactivity-FACS
FACS assay shows that recombinant Biotinylated FACS

FACS analysis shows that the binding of rituximab to 293F overexpressing CD20 was inhibited by increasing concentration of Anti-Rituximab Antibodies (Cat. No. RIB-Y37). The concentration of rituximab used is 10 ng/ml. The IC50 is 0.019 μg/ml (Routinely tested).

  • Background
    Rituxan is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light- and heavy-chain variable region sequences and human constant region sequences. Rituximab is composed of two heavy chains of 451 amino acids and two light chains of 213 amino acids.
  • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

Comments (0)

Order Details

Price(USD) : $300.00

Price(USD) : $1980.00

Promotion & Exhibitions

  • PEGS Boston 2019
  • PepTalk 2019

Datasheet & Documentation

Contact Us

+1  800-810-0816 (US)
+86 400-682-2521 (AP)

Questions & Comments

This web search service is supported by Google Inc.

totop